Cargando…
Liver Injury Following Isoniazid Preventive Therapy in HIV Patients Attending Halibet National Referral Hospital, Eritrea: A Prospective Cohort Study
INTRODUCTION: A 6-month course of isoniazid, 300 mg daily, was programmatically introduced in Eritrea in 2014 as tuberculosis preventive therapy in people living with human immunodeficiency virus (PLHIV). The rollout of isoniazid preventive therapy (IPT) in PLHIV was successful in the first 2–3 year...
Autores principales: | Russom, Mulugeta, Jeannetot, Daniel Y. B., Berhane, Araia, Woldu, Henok G., Stricker, Bruno H., Verhamme, Katia M. C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248330/ https://www.ncbi.nlm.nih.gov/pubmed/37289412 http://dx.doi.org/10.1007/s40801-023-00375-1 |
Ejemplares similares
-
Effectiveness of a 6-Month Isoniazid on Prevention of Incident Tuberculosis Among People Living with HIV in Eritrea: A Retrospective Cohort Study
por: Russom, Mulugeta, et al.
Publicado: (2022) -
Perspectives of Healthcare Professionals on Factors Limiting Implementation of Isoniazid Preventive Therapy in People Living with HIV in Eritrea: A Qualitative Study
por: Russom, Mulugeta, et al.
Publicado: (2022) -
Serious hepatotoxicity following use of isoniazid preventive therapy in HIV patients in Eritrea
por: Russom, Mulugeta, et al.
Publicado: (2018) -
Rapid diagnostic tests failing to detect Plasmodium falciparum infections in Eritrea: an investigation of reported false negative RDT results
por: Berhane, Araia, et al.
Publicado: (2017) -
Risk Factors of Gout in MDR-TB Patients in Eritrea: A Case-Control Study
por: Russom, Mulugeta, et al.
Publicado: (2019)